Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions (1:1)

Inclusion Criteria: * The patient or his/her representative must have given free and informed consent and signed the consent * The patient must be insured or beneficiary of a health insurance plan * The patient is available for 12 months of follow-up * The patient underwent a successful transcutaneous implant procedure for an aortic valve * The patient required anticoagulant treatment (AVK or DOAC) excepted rivaroxaban the day of inclusion * The patient is stable on anticoagulant treatment Exclusion Criteria: * The patient is participating in another study * The patient is in an exclusion period determined by a previous study * The patient or his/her representative refuses to sign the consent * It is impossible to correctly inform the patient or his/her representative * The patient is pregnant or breastfeeding * The patient has a contraindication (or an incompatible drug association) for a treatment used in this study * The patient had a coronary stent for less than 12 months * The patient does not require treatment with aspirin or any other antiplatelet agent * The patient has a history of aspirin allergy * High bleeding risk; such as platelets \<50,000 / mm3 during screening, Hb \<8.5 g / dL, history of intracranial hemorrhage or subdural hematoma, major surgery, parenchymal organ biopsy or severe trauma within 30 days before inclusion, active gastrointestinal ulcer in the last 3 months; * History of Stroke in the last 3 months; * Moderate or severe liver affection associated with coagulopathy * Active infectious endocarditis * Active tumor treated at the time of inclusion associated with expected survival less than one year * Not following countraindications specific to the molecules used fo the patients receiving DOAC